Impact of overweight and obesity on cardiac benefit of antihypertensive treatment
Introduction
The increased prevalence of hypertension and diabetes in obese subjects has been suggested to at least partly explain the increased cardiovascular risk observed in obesity [1], [2]. In hypertensive populations obesity has been associated with higher prevalence of left ventricular (LV) hypertrophy as well as lower LV systolic function [3], [4], [5]. It is well known that systematic antihypertensive treatment induces regression of hypertensive LV hypertrophy [6]. However, as documented from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study that randomized 9193 hypertensive patients with signs of LV hypertrophy on the electrocardiogram to 4.8 years blinded losartan- or atenolol-based antihypertensive treatment, concomitant obesity predicted increased cardiovascular mortality during follow-up independent of other individual cardiovascular risk factors and type of antihypertensive treatment [7]. Furthermore, clustering of metabolic abnormalities has been associated with blunted reduction in hypertensive LV hypertrophy assessed by electrocardiography [8].
Less is known about the impact of obesity on cardiac benefit, including regression of LV hypertrophy and improvement of LV systolic function measured by serial echocardiograms during systematic long-term antihypertensive treatment. Thus, the aim of the present analysis was to assess whether obesity itself attenuates the known beneficial effects of aggressive antihypertensive treatment on LV structure and systolic function.
Section snippets
Patient population
The present analysis was added to the LIFE echocardiography analysis plan before unblinding of data. The LIFE echocardiography study, a prospectively planned substudy of the main LIFE study, enrolled 960 of the 9193 participants in the parent trial for annual echocardiographic follow-up [9]. Results from the main LIFE study that randomized patients aged 55–80 years with essential hypertension (baseline blood pressure 160–200/95–115 mm Hg) and electrocardiographic (ECG) LV hypertrophy (according
Results
At baseline, obese patients groups were younger, and included more women and patients with diabetes and of African American ethnicity (all p < 0.01), while blood pressure was comparable between groups (Table 1). Baseline LV dimensions and wall thicknesses increased progressively with increasing BMI class, and prevalence of LV hypertrophy was significantly higher in overweight and obese groups than in the normal weight group (Table 2, Fig. 1).
During antihypertensive treatment, BMI and body
Discussion
The purpose of this study was to evaluate the impact of obesity on cardiac benefit including regression of LV hypertrophy and improvement of LV systolic function, during systematic long-term antihypertensive treatment. As expected from previous publications, obese patient groups had higher prevalence of LV hypertrophy before starting antihypertensive treatment [3], [4], [5]. However, our findings add to previous knowledge by demonstrating that regression of LV hypertrophy and improvement in LV
Conclusions
In hypertensive patients, obesity is associated with less regression of echocardiographic LV hypertrophy as well as less improvement of LV systolic function during antihypertensive treatment independent of concomitant diabetes. These findings may help explain the increased rate of cardiovascular events observed among obese hypertensive patients participating in the LIFE study despite a beneficial shift from concentric to eccentric LV hypertrophy pattern.
Disclosures
E.G., K.W., K.B. and M.S.N. have all received grant support from Merck & Co, the sponsor of the LIFE study. R.B.D. and B.D. have received grant support and served as consultants for Merck & Co. B.P.L. and G.d.S. have no disclosures relating to this manuscript.
Acknowledgment
The LIFE echocardiography substudy was supported in part by grant COZ-368 from Merck & Co, Inc., West Point, PA, USA (the sponsor of the parent LIFE study).
References (38)
- et al.
Importance of obesity, race and age to the cardiac structural abd functional effects of hypertension: the department of veterans affairs cooperative study group on antihypertensive agents
J Am Coll Cardiol
(1994) - et al.
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study
Nutr Metab Cardiovasc Dis
(2009) - et al.
LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet
(2002) - et al.
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint
Am J Cardiol
(2000) - et al.
Chamber quantification writing group; American society of echocardiography’s guidelines and standards committee; European association of echocardiography. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology
J Am Soc Echocardiogr
(2005) - et al.
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study
J Am Coll Cardiol
(1999) - et al.
Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The hypertension genetic epidemiology network study)
Am J Cardiol
(2001) - et al.
Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults
J Am Coll Cardiol
(1996) - et al.
Assessment of left ventricular function by midwall fractional shortening/end-systolic stress relation in human hypertension
J Am Coll Cardiol
(1994) - et al.
Prevalence and correlates of mitral regurgitation in a population-based sample (the strong heart study)
Am J Cardiol
(2001)
Prevalence and correlates of aortic regurgitation in American Indians: the strong heart study
J Am Coll Cardiol
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study
Nutr Metab Cardiovasc Dis
Central obesity: association with left ventricular dysfunction and mortality in the community
Am Heart J
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience
Arch Intern Med
Body mass index and mortality in a prospective cohort of U.S. adults
N Engl J Med
Influence of obesity on left ventricular midwall mechanics in arterial hypertension
Hypertension
Left ventricular filling in arterial hypertension. Influence of obesity and hemodynamic and structural confounders
Hypertension
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
Circulation
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study
Circulation
Cited by (26)
Left ventricular myocardial oxygen demand and subclinical dysfunction in patients with severe obesity referred for bariatric surgery
2021, Nutrition, Metabolism and Cardiovascular DiseasesAdiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study
2020, American Journal of Kidney DiseasesCitation Excerpt :In a pre-post study of morbidly obese adolescents who underwent bariatric surgery, LVMI decrease of 12 g/m2.7 was observed.27 Knowing that: (1) adiposity is as prevalent among children with CKD as within the general US population28,29; (2) CVD risk factors track from childhood to adulthood,30,31 with childhood BMI a strong predictor of adult LVH32; (3) LVH is a known risk factor for cardiac arrhythmias, diastolic dysfunction, and heart failure33; (4) comorbid obesity not only impairs the ability to effectively treat hypertensive LVH, but can also lead to a greater likelihood of CV events34-36; and (5) CVD statistics in adults also differ by sex,37 our findings suggest both an urgent need for enhanced obesity prevention and treatment in pediatric CKD and a potential role for targeted interventions. Adiposity contributes to LVH both directly and indirectly by its effect on BP, and sex differences in BP trends among children and adults have been well described.
Effect of fitness on cardiac structure and function in overweight and obesity (the FATCOR study)
2019, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :Additionally, epicardial fat may infiltrate the myocardium, resulting in myocardial steatosis [22]. Previous studies have documented the association of obesity with lower LV systolic chamber and myocardial function [1,5,6,23]. The present study adds to this by demonstrating that among obese subjects without known CV disease, having at least good fitness was associated with higher LV myocardial function assessed by GLS, particularly related to a lower body fat percentage, while no impact was found on myocardial function in overweight subjects.
Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: The Campania Salute Network
2019, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :There is definitely a need for better weight reduction programs in obese hypertensive patients with increased LVMi. In clinical practice, patients with combined obesity and hypertension are particularly challenging to treat and BP often remain sub-optimally controlled [2,3,7]. Our results strongly indicate that in the presence of obesity, antihypertensive treatment should always be combined with programs of weight reduction, to improve BP control and to favor reduction of LVMi.
Sex differences in subclinical cardiac disease in overweight and obesity (the FATCOR study)
2018, Nutrition, Metabolism and Cardiovascular DiseasesLeft ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network)
2018, International Journal of Cardiology